In this issue of the *BJD*, McAleer *et al*. present interesting and important research on biomarkers measured in stratum corneum and plasma of infants with atopic dermatitis (AD).[1](#bjd17411-bib-0001){ref-type="ref"} Although AD is much more common in childhood, most biomarker research until now has focused on the disease in adults. With many new drugs for children with AD in different stages of development this research is timely.

There are many different uses for biomarkers in AD,[2](#bjd17411-bib-0002){ref-type="ref"} among these are the objective determination of disease severity and the prediction of treatment response. Until now, disease severity in patients with AD is mostly determined by using clinician‐rated severity scores \[e.g. Six Area, Six Sign Atopic Dermatitis, the Eczema Area and Severity Index (EASI) and the Severity Scoring of Atopic Dermatitis index (SCORAD)\], each of which has advantages and disadvantages. The search for better clinician‐rated disease severity measures in AD has resulted in more than 20 different scores being used in clinical studies, which hampers study comparability. Although the EASI and SCORAD are now the preferred measures, they also both have the problem of high inter‐ and intraobserver variability.[3](#bjd17411-bib-0003){ref-type="ref"} An objective biomarker for disease severity determined in blood or skin could greatly improve the way we measure disease severity in AD.

A recent systematic review showed serum CCL17/TARC levels to be the best objective biomarker for disease severity in adults with AD.[4](#bjd17411-bib-0004){ref-type="ref"} Now McAleer *et al*. have confirmed that AD plasma CCL17/TARC levels also correlates to disease severity in children.[1](#bjd17411-bib-0001){ref-type="ref"} Their study comprised the investigation of a set of potential biomarkers in stratum corneum. The user‐friendly availability of less‐invasive techniques for biomarker retrieval, such as tape stripping or the use of dried blood spots, can greatly expand their use, which will result in increased knowledge on processes involved in the early development of the disease. These developments may also help us to explain the heterogeneity of the disease and underlying pathways that will determine the specific path a child will follow in the atopic disease march better.

It is interesting to read about the comparison of blood and skin biomarkers in McAleer *et al*.\'s study, as some biomarkers are known to be expressed highly in the skin, but difficult to measure in blood. Cytokines and chemokines produced in the skin can be measured in blood after diffusion from skin into blood or after expression (e.g. chemokines) on endothelial cells and subsequent shedding into the circulation. The concentrations of these skin‐derived inflammatory biomarkers in blood gives an indication of the inflammatory activity encompassing the total skin surface.

In contrast, biomarker levels measured in tape strips only reflect the 'local level of inflammation' in the sampled area. Correlating disease severity with expression of biomarkers in tape strips is therefore less likely to correlate to a disease severity measure that encompasses the total skin area. Biomarkers measured in the stratum corneum may, however, be helpful in the identification of patients with different endophenotypes. Indeed, our research group have recently described different clusters of adults with AD based on serum biomarker expression levels, that may represent different endophenotypes.[5](#bjd17411-bib-0005){ref-type="ref"} Thus, the use of noninvasive biomarker sampling methods paves the way for large‐scale endophenotyping in both children and adults. As patients with different endophenotypes are supposed to respond differently to new, highly targeted treatments, this may help us with the identification of the right patient for the right drug on our journey to precision medicine.

Thanks to Dr Lia Kunkeler for her critical review of this commentary.
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